Company / Free Cash Flow
Vaxcyte, Inc. Free Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$669.3M
FY2025
5-year range
-$669.3M / -$127.9M
FY2021-FY2025
Trend
-40.9%
vs FY2024
Sector context
#190 of 194
Health Care
What the data says
Among 194 Health Care companies, Vaxcyte, Inc. is in the bottom 2% for free cash flow. Free Cash Flow has declined for 5 consecutive years, from -$48M in FY2020 to -$669M in FY2025.
Based on SEC 10-K filings.
-$669M in FY2025.
Declined from -$313M to -$669M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 194This company -$669.3M Sector average $470.6M
▼
-242.2% below sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s free cash flow has declined for 5 consecutive years.
- In FY2025, free cash flow decreased 40.9% year-over-year.
- Ranks #190 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$669.3M | -40.9% |
| FY2024 | -$475.1M | -51.8% |
| FY2023 | -$312.9M | -77.3% |
| FY2022 | -$176.4M | -37.9% |
| FY2021 | -$127.9M | -167.8% |
| FY2020 | -$47.8M | +1.2% |
| FY2019 | -$48.3M | -49.9% |
| FY2018 | -$32.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026